Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics
Sponsor: University of Wisconsin, Madison
Summary
This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.
Key Details
Gender
All
Age Range
21 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
5
Start Date
2026-10
Completion Date
2027-03
Last Updated
2026-08-11
Healthy Volunteers
Yes
Interventions
Acute Ethanol Dose
Time 0, participants will self-administer an oral ethanol beverage (vodka and sugar-free cherry Kool aid) calculated to reach a peak Breath Alcohol Concentration (BrAC) of 0.08 g/dL using the Widmark formula. A total time of 30 minutes will be given for completion of beverage consumption. This will be followed by a breakfast.
Locations (1)
University of Wisconsin
Madison, Wisconsin, United States